Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.

Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC.

Br J Haematol. 2013 May;161(4):499-507. doi: 10.1111/bjh.12280. Epub 2013 Feb 26.

PMID:
23438504
2.

Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma.

Syrigos KN, Harrington KJ, Karayiannakis AJ, Baibas N, Katirtzoglou N, Roussou P.

Anticancer Res. 2004 May-Jun;24(3b):2027-31.

3.

The prognostic value of cadherin switch in bladder cancer.

Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S, Szarvas T.

Oncol Rep. 2010 Apr;23(4):1125-32.

PMID:
20204300
4.

Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.

Vagnoni D, Travaglini F, Pezzoni V, Ruggieri M, Bigazzi C, Dalsass A, Mestichelli F, Troiani E, Falcioni S, Mazzotta S, Natale A, Angelini M, Ferretti S, Angelini S, Galieni P.

Br J Haematol. 2015 Aug;170(4):523-31. doi: 10.1111/bjh.13484. Epub 2015 May 26.

PMID:
26010293
5.

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H.

Clin Cancer Res. 2006 May 1;12(9):2780-7.

7.

Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.

Gastinne T, Leleu X, Duhamel A, Moreau AS, Franck G, Andrieux J, Lai JL, Coiteux V, Yakoub-Agha I, Bauters F, Harousseau JL, Zandecki M, Facon T; Intergroupe Francophone du Myelome (IFM).

Eur J Haematol. 2007 Oct;79(4):297-304. Epub 2007 Aug 10.

PMID:
17692103
8.

Clinical significance of serum soluble E-cadherin in colorectal carcinoma.

Okugawa Y, Toiyama Y, Inoue Y, Iwata T, Fujikawa H, Saigusa S, Konishi N, Tanaka K, Uchida K, Kusunoki M.

J Surg Res. 2012 Jun 15;175(2):e67-73. doi: 10.1016/j.jss.2011.11.009. Epub 2011 Nov 30.

PMID:
22277332
9.

Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer.

Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, Ko S, Hui WM, Yueng YH, Wong J.

J Clin Oncol. 2003 Jun 15;21(12):2288-93.

PMID:
12805328
10.

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.

Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A, Heider U, Fleissner C, Kaiser M, von Metzler I, Müller C, Sezer O.

Leukemia. 2008 Sep;22(9):1767-72. doi: 10.1038/leu.2008.159. Epub 2008 Jun 26. Erratum in: Leukemia. 2008 Sep;22(9):1812.

PMID:
18580957
11.

Soluble E-cadherin is a valid prognostic marker in gastric carcinoma.

Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC, Wong CY, Hu HC, Lai CL, Wong J.

Gut. 2001 Jun;48(6):808-11.

12.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group.

Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638.

13.

sVE-cadherin and sCD146 serum levels in patients with multiple myeloma.

Wrobel T, Mazur G, Wolowiec D, Jazwiec B, Sowinska E, Kuliczkowski K.

Clin Lab Haematol. 2006 Feb;28(1):36-9.

PMID:
16430458
14.

Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.

Scudla V, Ordeltova M, Minarik J, Dusek L, Zemanova M, Bacovsky J.

Neoplasma. 2006;53(3):213-8.

PMID:
16652190
15.

Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.

Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.

Eur J Haematol. 2006 Jan;76(1):51-7.

PMID:
16343271
16.

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative.

Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15.

PMID:
22333880
17.

A new staging system for multiple myeloma based on the number of S-phase plasma cells.

San Miguel JF, García-Sanz R, González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R, et al.

Blood. 1995 Jan 15;85(2):448-55.

18.

Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.

Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ.

Clin Cancer Res. 2004 Aug 15;10(16):5546-53.

19.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.

Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.

20.

Circulating levels and clinical significance of soluble CD86 in myeloma patients.

Hock BD, Drayson M, Patton WN, Taylor K, Kerr L, McKenzie JL.

Br J Haematol. 2006 Apr;133(2):165-72.

PMID:
16611307

Supplemental Content

Support Center